Momenta Pharmaceuticals Company Profile (NASDAQ:MNTA)

About Momenta Pharmaceuticals

Momenta Pharmaceuticals logoMomenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox (enoxaparin sodium injection). Its GLATOPA is a generic version of once-daily COPAXONE 20 milligrams/milliliter (mg/mL) indicated for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS), a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. It is developing M923, which is a biosimilar of HUMIRA and M834 as a biosimilar of ORENCIA. Its oncology product candidate Necuparanib, is an oncology product candidate, which have a range of effects on tumor cells and the environment, in which tumor cells grow. It focuses on M281, which is an Anti-FcRn program.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: MNTA
  • CUSIP: 60877T10
Key Metrics:
  • Previous Close: $15.10
  • 50 Day Moving Average: $16.85
  • 200 Day Moving Average: $13.78
  • 52-Week Range: $7.86 - $19.90
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 65.65
  • P/E Growth: 0.00
  • Market Cap: $1.04B
  • Outstanding Shares: 68,957,000
  • Beta: 1.81
Profitability:
  • Net Margins: -93.75%
  • Return on Equity: -26.55%
  • Return on Assets: -21.69%
Debt:
  • Current Ratio: 7.47%
  • Quick Ratio: 7.47%
Additional Links:
Companies Related to Momenta Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Momenta Pharmaceuticals (NASDAQ:MNTA) (?)
Ratings Breakdown: 1 Sell Rating, 4 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $16.56 (9.64% upside)

Analysts' Ratings History for Momenta Pharmaceuticals (NASDAQ:MNTA)
Show:
DateFirmActionRatingPrice TargetDetails
2/21/2017Leerink SwannDowngradeOutperform -> Market Perform$18.00 -> $18.00View Rating Details
2/21/2017AegisReiterated RatingHold$17.00View Rating Details
2/1/2017Maxim GroupReiterated RatingSell$6.00View Rating Details
1/31/2017Barclays PLCBoost Price TargetOverweight$19.00 -> $20.00View Rating Details
1/8/2017Stifel NicolausReiterated RatingBuy$20.00View Rating Details
11/3/2016J P Morgan Chase & CoReiterated RatingBuy$18.00View Rating Details
8/7/2016Cowen and CompanyReiterated RatingHoldView Rating Details
8/5/2016Brean CapitalSet Price TargetBuy$19.00View Rating Details
6/6/2016Goldman Sachs Group, Inc. (The)Initiated CoverageNeutral$14.00View Rating Details
8/24/2015Sanford C. BernsteinReiterated RatingBuyView Rating Details
(Data available from 2/22/2015 forward)

Earnings

Earnings History for Momenta Pharmaceuticals (NASDAQ:MNTA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2017        
2/21/2017Q416($0.24)$0.60$29.56 million$34.20 millionViewN/AView Earnings Details
11/2/2016Q316($0.29)($0.26)$25.68 million$299.14 millionViewN/AView Earnings Details
8/4/2016Q216($0.32)($0.31)$23.55 million$26.40 millionViewN/AView Earnings Details
5/3/2016Q116($0.32)($0.35)$28.12 million$19.90 millionViewN/AView Earnings Details
2/18/2016Q415($0.04)($0.43)$30.42 million$22.40 millionViewListenView Earnings Details
11/4/2015Q315($0.19)($0.44)$31.76 million$13.80 millionViewListenView Earnings Details
8/4/2015Q215($0.39)($0.04)$23.59 million$44.90 millionViewListenView Earnings Details
5/1/2015Q115($0.48)($0.40)$11.70 million$8.60 millionViewN/AView Earnings Details
2/17/2015Q414($0.26)($0.31)$23.80 million$21.18 millionViewListenView Earnings Details
11/5/2014Q314($0.43)($0.56)$13.00 million$9.34 millionViewListenView Earnings Details
7/31/2014Q214($0.46)($0.51)$11.22 million$11.00 millionViewListenView Earnings Details
5/6/2014Q1($0.55)($0.53)$8.41 million$10.79 millionViewListenView Earnings Details
2/10/2014Q4($0.45)($0.59)$8.50 million$12.80 millionViewListenView Earnings Details
11/5/2013Q313($0.48)($0.50)$8.60 million$10.80 millionViewN/AView Earnings Details
8/1/2013Q2 2013($0.45)($0.57)$8.85 million$4.40 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.44)($0.48)$10.28 million$7.60 millionViewN/AView Earnings Details
2/15/2013Q4 2012($0.41)($0.35)$10.41 million$12.70 millionViewN/AView Earnings Details
11/7/2012Q312($0.27)($0.51)$16.48 million$5.10 millionViewN/AView Earnings Details
8/2/2012($0.17)($0.20)ViewN/AView Earnings Details
5/3/2012$0.02($0.10)ViewN/AView Earnings Details
2/9/2012$0.13($0.02)ViewN/AView Earnings Details
11/7/2011$1.28$1.18ViewN/AView Earnings Details
8/4/2011$1.21$1.26ViewN/AView Earnings Details
5/5/2011$0.95$1.13ViewN/AView Earnings Details
2/10/2011$0.81$0.77ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Momenta Pharmaceuticals (NASDAQ:MNTA)
Current Year EPS Consensus Estimate: $-1.18 EPS
Next Year EPS Consensus Estimate: $0.23 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.36)($0.36)($0.36)
Q3 20161($0.34)($0.34)($0.34)
Q4 20161($0.29)($0.29)($0.29)
Q1 20171($0.22)($0.22)($0.22)
Q2 20171($0.20)($0.20)($0.20)
Q3 20171$0.06$0.06$0.06
Q4 20171($0.01)($0.01)($0.01)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Momenta Pharmaceuticals (NASDAQ:MNTA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Momenta Pharmaceuticals (NASDAQ:MNTA)
Insider Ownership Percentage: 6.10%
Institutional Ownership Percentage: 84.44%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/15/2016Richard P SheaCFOSell9,799$15.00$146,985.00View SEC Filing  
12/9/2016Richard P SheaCFOSell1,451$15.00$21,765.00View SEC Filing  
11/22/2016Bruce LeicherSVPSell1,030$13.66$14,069.80View SEC Filing  
11/22/2016Craig A. WheelerPresidentSell5,880$13.68$80,438.40View SEC Filing  
11/22/2016James M RoachVPSell1,091$13.67$14,913.97View SEC Filing  
11/22/2016Richard P SheaCFOSell971$13.67$13,273.57View SEC Filing  
8/22/2016Bruce LeicherSVPSell1,030$12.05$12,411.50View SEC Filing  
8/22/2016Craig A. WheelerPresidentSell5,880$12.02$70,677.60View SEC Filing  
8/22/2016James M RoachVPSell1,091$12.05$13,146.55View SEC Filing  
8/22/2016Richard P SheaCFOSell972$12.05$11,712.60View SEC Filing  
5/20/2016Bruce LeicherSVPSell1,000$10.40$10,400.00View SEC Filing  
5/20/2016Craig A WheelerPresidentSell5,880$10.18$59,858.40View SEC Filing  
5/20/2016Ganesh Venkataraman KaundinyaVPSell1,050$10.18$10,689.00View SEC Filing  
5/20/2016Richard P SheaCFOSell973$10.18$9,905.14View SEC Filing  
5/19/2016John E BishopVPSell784$10.20$7,996.80View SEC Filing  
4/19/2016John E BishopVPSell2,843$9.57$27,207.51View SEC Filing  
2/23/2016John E BishopVPSell329$9.70$3,191.30View SEC Filing  
2/22/2016Bruce LeicherSVPSell227$9.65$2,190.55View SEC Filing  
2/22/2016Craig A WheelerPresidentSell1,688$9.95$16,795.60View SEC Filing  
2/22/2016John E BishopVPSell2,848$9.66$27,511.68View SEC Filing  
2/19/2016Bruce LeicherSVPSell2,000$9.64$19,280.00View SEC Filing  
2/19/2016Craig A WheelerPresidentSell9,844$9.37$92,238.28View SEC Filing  
2/19/2016John E. BishopVPSell357$10.28$3,669.96View SEC Filing  
2/19/2016Richard P SheaCFOSell1,823$9.64$17,573.72View SEC Filing  
2/18/2016Bruce LeicherSVPSell337$10.49$3,535.13View SEC Filing  
2/18/2016James M RoachVPSell272$10.49$2,853.28View SEC Filing  
2/18/2016Richard P SheaCFOSell183$10.49$1,919.67View SEC Filing  
2/17/2016Craig A WheelerPresidentSell1,688$11.30$19,074.40View SEC Filing  
12/11/2015Michael FrankenInsiderSell520$15.84$8,236.80View SEC Filing  
11/20/2015Craig A WheelerPresidentSell1,766$17.86$31,540.76View SEC Filing  
11/19/2015Craig A WheelerPresidentSell2,061$18.05$37,201.05View SEC Filing  
11/17/2015Craig A WheelerPresidentSell1,766$17.70$31,258.20View SEC Filing  
11/5/2015Craig A. WheelerPresidentSell51,667$18.00$930,006.00View SEC Filing  
8/20/2015Craig A WheelerPresidentSell1,766$22.28$39,346.48View SEC Filing  
8/19/2015Craig A WheelerPresidentSell2,061$22.02$45,383.22View SEC Filing  
8/19/2015James M. RoachVPSell7,011$22.09$154,872.99View SEC Filing  
8/18/2015James M RoachVPSell6,812$21.80$148,501.60View SEC Filing  
8/17/2015Craig A WheelerPresidentSell1,766$21.77$38,445.82View SEC Filing  
7/15/2015Elizabeth StonerDirectorSell4,570$22.35$102,139.50View SEC Filing  
6/19/2015John E BishopVPSell21,274$25.50$542,487.00View SEC Filing  
6/18/2015Bruce LeicherSVPSell20,000$23.00$460,000.00View SEC Filing  
6/18/2015Craig A WheelerPresidentSell155,000$24.20$3,751,000.00View SEC Filing  
6/18/2015John E BishopVPSell36,313$23.58$856,260.54View SEC Filing  
6/4/2015Craig A WheelerPresidentSell103,333$22.00$2,273,326.00View SEC Filing  
6/1/2015Bruce LeicherSVPSell40,000$21.00$840,000.00View SEC Filing  
6/1/2015James M RoachVPSell25,000$21.70$542,500.00View SEC Filing  
5/20/2015Craig A WheelerPresidentSell1,766$19.68$34,754.88View SEC Filing  
5/19/2015Craig A WheelerPresidentSell2,061$19.67$40,539.87View SEC Filing  
4/23/2015Craig A WheelerPresidentSell51,667$20.00$1,033,340.00View SEC Filing  
4/23/2015Ganesh Venkataraman KaundinyaVPSell34,000$19.95$678,300.00View SEC Filing  
4/20/2015Craig A WheelerPresidentSell6,269$18.75$117,543.75View SEC Filing  
4/17/2015Bruce LeicherSVPSell52,910$19.52$1,032,803.20View SEC Filing  
4/16/2015James M RoachVPSell50,000$18.70$935,000.00View SEC Filing  
3/16/2015Richard P SheaCFOSell23,093$15.10$348,704.30View SEC Filing  
3/5/2015Richard P SheaCFOSell23,364$14.90$348,123.60View SEC Filing  
2/24/2015Craig A WheelerPresidentSell2,110$13.52$28,527.20View SEC Filing  
2/20/2015Bruce LeicherSVPSell1,891$12.97$24,526.27View SEC Filing  
2/20/2015Craig A WheelerPresidentSell9,563$13.49$129,004.87View SEC Filing  
2/20/2015John E BishopVPSell1,768$12.97$22,930.96View SEC Filing  
2/20/2015Richard P SheaCFOSell1,812$12.97$23,501.64View SEC Filing  
2/18/2015Craig A WheelerPresidentSell1,688$11.91$20,104.08View SEC Filing  
12/15/2014Bennett M ShapiroDirectorSell5,800$12.19$70,702.00View SEC Filing  
12/11/2014Michael FrankenInsiderSell2,047$12.29$25,157.63View SEC Filing  
12/1/2014Bennett M ShapiroDirectorSell9,903$12.00$118,836.00View SEC Filing  
11/28/2014Bennett M ShapiroDirectorSell1,897$12.00$22,764.00View SEC Filing  
11/25/2014Craig A WheelerPresidentSell2,210$11.59$25,613.90View SEC Filing  
11/20/2014Craig A WheelerPresidentSell1,768$11.10$19,624.80View SEC Filing  
11/17/2014Craig A WheelerPresidentSell1,768$10.58$18,705.44View SEC Filing  
10/3/2014Bennett M ShapiroDirectorSell3,723$12.00$44,676.00View SEC Filing  
9/12/2014Peter Barton HuttDirectorSell3,640$11.42$41,568.80View SEC Filing  
8/25/2014Craig A WheelerPresidentSell2,209$11.45$25,293.05View SEC Filing  
8/20/2014Craig A WheelerPresidentSell1,768$11.54$20,402.72View SEC Filing  
8/15/2014Bennett M ShapiroDirectorSell3,722$12.00$44,664.00View SEC Filing  
8/15/2014Craig A WheelerPresidentSell1,768$11.75$20,774.00View SEC Filing  
8/13/2014Bennett M ShapiroDirectorSell3,721$12.00$44,652.00View SEC Filing  
5/23/2014Craig A WheelerPresidentSell2,110$12.06$25,446.60View SEC Filing  
5/20/2014Craig WheelerPresidentSell1,688$12.08$20,391.04View SEC Filing  
5/15/2014Craig WheelerPresidentSell1,687$11.09$18,708.83View SEC Filing  
2/25/2014Craig WheelerPresidentSell2,109$17.47$36,844.23View SEC Filing  
2/24/2014John BishopVPSell1,038$17.67$18,341.46View SEC Filing  
2/19/2014Craig WheelerPresidentSell3,797$17.90$67,966.30View SEC Filing  
2/12/2014Ganesh Venkataraman KaundinyaVPSell33,000$17.96$592,680.00View SEC Filing  
1/9/2014John BishopVPSell27,159$19.50$529,600.50View SEC Filing  
11/25/2013Bruce LeicherSVPSell13,492$18.00$242,856.00View SEC Filing  
11/25/2013Craig WheelerPresidentSell2,215$17.77$39,360.55View SEC Filing  
11/25/2013Ganesh Venkataraman KaundinyaVPSell33,211$18.02$598,462.22View SEC Filing  
11/19/2013Craig WheelerPresidentSell2,215$17.17$38,031.55View SEC Filing  
11/15/2013Craig WheelerPresidentSell1,772$16.88$29,911.36View SEC Filing  
10/11/2013John BishopVPSell5,247$15.46$81,118.62View SEC Filing  
8/23/2013Craig WheelerPresidentSell2,109$14.90$31,424.10View SEC Filing  
8/20/2013Craig WheelerPresidentSell2,109$14.47$30,517.23View SEC Filing  
8/15/2013Craig WheelerPresidentSell1,688$15.43$26,045.84View SEC Filing  
7/26/2013Richard P SheaCFOSell30,000$16.61$498,300.00View SEC Filing  
6/27/2013Richard P SheaCFOSell10,522$14.61$153,726.42View SEC Filing  
6/19/2013Richard P SheaCFOSell21,550$14.61$314,845.50View SEC Filing  
5/23/2013Craig A WheelerPresidentSell2,109$13.03$27,480.27View SEC Filing  
5/21/2013Craig A WheelerPresidentSell2,109$12.83$27,058.47View SEC Filing  
5/15/2013Craig A WheelerPresidentSell1,687$13.33$22,487.71View SEC Filing  
3/5/2013Elizabeth StonerDirectorSell2,040$14.00$28,560.00View SEC Filing  
2/15/2013Bruce LeicherSVPSell1,040$12.26$12,750.40View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Momenta Pharmaceuticals (NASDAQ:MNTA)
DateHeadline
News IconMomenta Pharmaceuticals, Inc. (MNTA) Lowered to Market Perform at Leerink Swann (NASDAQ:MNTA)
naijaoversabi.com - February 22 at 6:43 PM
investopedia.com logoMomenta 4Q Net 60 Cents a Share (MNTA) (NASDAQ:MNTA)
www.investopedia.com - February 22 at 6:43 PM
us.rd.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Momenta Pharmaceuticals, Inc. (MNTA) (NASDAQ:MNTA)
us.rd.yahoo.com - February 22 at 6:43 PM
capitalcube.com logoMomenta Pharmaceuticals, Inc. :MNTA-US: Earnings Analysis: Q4, 2016 By the Numbers : February 22, 2017 (NASDAQ:MNTA)
us.rd.yahoo.com - February 22 at 6:43 PM
us.rd.yahoo.com logoINVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Momenta Pharmaceuticals, Inc. Investors (NASDAQ:MNTA)
us.rd.yahoo.com - February 22 at 6:43 PM
us.rd.yahoo.com logoMomenta 4Q Net 60 Cents a Share (NASDAQ:MNTA)
us.rd.yahoo.com - February 22 at 6:43 PM
us.rd.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving the Board of Momenta Pharmaceuticals, Inc. -- MNTA (NASDAQ:MNTA)
us.rd.yahoo.com - February 22 at 6:43 PM
finance.yahoo.com logoIMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Momenta Pharmaceuticals, Inc., and Encourages Investors to Contact the Firm (NASDAQ:MNTA)
finance.yahoo.com - February 22 at 6:43 PM
finance.yahoo.com logoMomenta Tops Q4 Earnings, Shares Down on Warning Letter (NASDAQ:MNTA)
finance.yahoo.com - February 22 at 6:43 PM
fool.com logoMomenta Pharmaceuticals, Inc. Earnings Take a Back Seat (NASDAQ:MNTA)
www.fool.com - February 22 at 3:57 PM
News IconWhy Momenta Pharmaceuticals, Northern Dynasty Minerals, and Unilever Slumped Today - Madison.com (NASDAQ:MNTA)
host.madison.com - February 22 at 8:28 AM
businesswire.com logoSHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Momenta Pharmaceuticals, Inc. and ... - Business Wire (press release) (NASDAQ:MNTA)
www.businesswire.com - February 22 at 8:28 AM
finance.yahoo.com logo2:08 am Momenta Pharma receives FDA warning letter for contracted Glatopa - approval of the Glatopa 40mg ANDA will be dependent on resolution of Pfizer (PFE (NASDAQ:MNTA)
finance.yahoo.com - February 22 at 8:28 AM
finance.yahoo.com logoAnalysts' Actions -- Discovery, First Solar, Momenta, VF Corp. and More (NASDAQ:MNTA)
finance.yahoo.com - February 22 at 8:28 AM
capitalcube.com logoMomenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : MNTA-US : February 22, 2017 (NASDAQ:MNTA)
www.capitalcube.com - February 22 at 8:28 AM
News IconVolatility Spiking as Shares Ride the Wave: Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) - Aiken Advocate (NASDAQ:MNTA)
aikenadvocate.com - February 21 at 6:18 PM
smarteranalyst.com logoTuesday's Market Insights: DryShips Inc. (DRYS), Momenta Pharmaceuticals, Inc. (MNTA), Cidara Therapeutics Inc ... - Smarter Analyst (NASDAQ:MNTA)
www.smarteranalyst.com - February 21 at 6:18 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Momenta Pharmaceuticals, Inc. - MNTA (NASDAQ:MNTA)
finance.yahoo.com - February 21 at 6:18 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Momenta Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm (NASDAQ:MNTA)
finance.yahoo.com - February 21 at 6:18 PM
fool.com logoWhy Momenta Pharmaceuticals, Northern Dynasty Minerals, and Unilever Slumped Today (NASDAQ:MNTA)
www.fool.com - February 21 at 6:18 PM
fool.com logoWhy Momenta Pharmaceuticals, Inc. Shares Got Crushed Today (NASDAQ:MNTA)
www.fool.com - February 21 at 1:48 PM
News IconMomenta Announces FDA Warning Letter To Contracted Glatopa (NASDAQ:MNTA)
www.biospace.com - February 20 at 10:03 AM
globenewswire.com logoMomenta Pharmaceuticals Announces FDA Warning Letter to Contracted Glatopa® (glatiramer acetate injection) Fill ... - GlobeNewswire (press release) (NASDAQ:MNTA)
globenewswire.com - February 19 at 9:53 AM
finance.yahoo.com logoMomenta Pharmaceuticals Announces Time Change for Fourth Quarter and Year End 2016 Financial Results ... - Yahoo Finance (NASDAQ:MNTA)
finance.yahoo.com - February 18 at 5:48 PM
marketwatch.com logoMomenta Pharma shares halted as drug application hits speed bump - MarketWatch (NASDAQ:MNTA)
www.marketwatch.com - February 18 at 5:48 PM
streetinsider.com logoMomenta Phama (MNTA) Says Glatopa Fill/Finish Manufacturing Partner Received an FDA Warning Letter (NASDAQ:MNTA)
www.streetinsider.com - February 18 at 12:26 PM
us.rd.yahoo.com logoMomenta Pharmaceuticals Announces FDA Warning Letter to Contracted Glatopa® (glatiramer acetate injection) Fill/Finish Manufacturer (NASDAQ:MNTA)
us.rd.yahoo.com - February 18 at 12:26 PM
marketwatch.com logoMomenta Pharma shares halted as drug application hits speed bump (NASDAQ:MNTA)
www.marketwatch.com - February 18 at 12:25 PM
feeds.benzinga.com logoMomenta Pharmaceuticals Announces Time Change for Fourth Quarter and Year End 2016 Financial Results Conference Call and Webcast (NASDAQ:MNTA)
feeds.benzinga.com - February 17 at 6:51 PM
streetinsider.com logoMomenta Phama (MNTA) Receives HSR Clearance for Collaboration and License Agreement with CSL (NASDAQ:MNTA)
www.streetinsider.com - February 17 at 4:01 PM
finance.yahoo.com logoMomenta Pharmaceuticals Announces HSR Clearance for Collaboration and License Agreement with CSL (NASDAQ:MNTA)
finance.yahoo.com - February 17 at 4:01 PM
News IconTrading Sheet: Reviewing the Levels for Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) - Davidson Register (NASDAQ:MNTA)
davidsonregister.com - February 14 at 8:09 PM
News IconStock Update: Focusing on Shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) - Midway Monitor (NASDAQ:MNTA)
midwaymonitor.com - February 14 at 8:09 PM
us.rd.yahoo.com logoTeva Pharm Q4 profit, revenue beat expectations (NASDAQ:MNTA)
us.rd.yahoo.com - February 13 at 7:45 PM
sg.finance.yahoo.com logoTeva seeks CEO with pharma background to lead recovery efforts (NASDAQ:MNTA)
sg.finance.yahoo.com - February 13 at 7:45 PM
finance.yahoo.com logoForget Gilead, Buy These 5 Biotech Stocks Instead (NASDAQ:MNTA)
finance.yahoo.com - February 13 at 10:18 AM
finance.yahoo.com logoCan The Uptrend Continue for Momenta Pharmaceuticals (MNTA)? (NASDAQ:MNTA)
finance.yahoo.com - February 10 at 5:40 AM
News IconShares in Review: Momenta Pharmaceuticals Inc. (MNTA) - Piedmont Register (NASDAQ:MNTA)
piedmontregister.com - February 8 at 5:57 AM
feeds.benzinga.com logoMomenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2016 Financial Results Conference Call and Webcast (NASDAQ:MNTA)
feeds.benzinga.com - February 7 at 9:19 AM
News IconMomenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Analytical Analysis - The Newburgh Press (NASDAQ:MNTA)
newburghpress.com - February 3 at 7:21 PM
News IconMomenta Pharmaceuticals, Inc. 25.8% Potential Upside Now Implied by Barclays (NASDAQ:MNTA)
viveremilano.biz - February 3 at 12:30 AM
istreetwire.com logoStocks Buzz: Blackstone Mortgage Trust, Inc. (BXMT), Momenta Pharmaceuticals, Inc. (MNTA), Palatin Technologies ... - iStreetWire (NASDAQ:MNTA)
istreetwire.com - February 2 at 7:28 PM
News IconNext Weeks Broker Price Targets For Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) (NASDAQ:MNTA)
cote-ivoire.com - February 2 at 12:31 AM
News IconWhat are Analysts report about: Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) (NASDAQ:MNTA)
emfizz.com - February 2 at 12:31 AM
rttnews.com logoMomenta Pharmaceuticals Inc. (MNTA) Surged To A New High On Patent Ruling (NASDAQ:MNTA)
www.rttnews.com - February 2 at 12:31 AM
News IconMomenta Pharmaceuticals (NASDAQ:MNTA) Receives 'Overweight' Rating From Brokers At Barclays Capital (NASDAQ:MNTA)
hoyentv.com - February 2 at 12:31 AM
News IconEarnings Forecast Research on Momenta Pharmaceuticals, Inc. (MNTA) (NASDAQ:MNTA)
onemma.net - February 2 at 12:31 AM
us.rd.yahoo.com logoMomenta Pharmaceuticals to Webcast Presentation at the Leerink Partners 6th Annual Global Healthcare Conference (NASDAQ:MNTA)
us.rd.yahoo.com - February 2 at 12:31 AM
News IconEarnings Parade Rolls On, What Are Analysts Saying About Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)? - Wall Street Beacon (NASDAQ:MNTA)
wsbeacon.com - February 1 at 7:30 PM
finance.yahoo.com logoMomenta Pharmaceuticals to Webcast Presentation at the Leerink ... - Yahoo Finance (NASDAQ:MNTA)
finance.yahoo.com - February 1 at 7:30 PM

Social

What is Momenta Pharmaceuticals' stock symbol?

Momenta Pharmaceuticals trades on the NASDAQ under the ticker symbol "MNTA."

Where is Momenta Pharmaceuticals' stock going? Where will Momenta Pharmaceuticals' stock price be in 2017?

9 equities research analysts have issued 12-month price objectives for Momenta Pharmaceuticals' stock. Their predictions range from $6.00 to $20.00. On average, they anticipate Momenta Pharmaceuticals' stock price to reach $16.56 in the next year.

When will Momenta Pharmaceuticals announce their earnings?

Momenta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, May, 1st 2017.

What are analysts saying about Momenta Pharmaceuticals stock?

Here are some recent quotes from research analysts about Momenta Pharmaceuticals stock:

  • Aegis analysts commented, "Warning letter delivered from FDA to fill/finish manufacturer. On Friday after market close, Momenta announced that Pfizer, Sandoz's contracted manufacturer for Glatopa, had received an FDA warning letter. While the facility is a key portion of Momenta's supply chain for Glatopa 20mg, the warning letter is not expected to restrict production or shipments. Since the Pfizer facility is where the final Glatopa 40 mg product will be manufactured, FDA policy states that compliance observations must be satisfactorily resolved before the ANDA can move forward. We anticipate this will translate into a 6-month delay for Glatopa 40 mg." (2/21/2017)
  • Maxim Group analysts commented, "The District Court of Delaware ruled to invalidate several of Teva’s (TEVA- $33.43-Hold) patents protecting 40mg (3x weekly) Copaxone; Patents ‘250, ‘413, ‘302, and ‘776. In 2016, the Patent Trial and Appeal Board (PTAB) declared these patents invalid due to obviousness through an inter partes review (IPR) proceeding." (2/1/2017)

  • According to Zacks Investment Research, "Momenta received a boost with the FDA approval of Glatopa (a generic version of Copaxone; 20 mg). The drug has captured nearly 40% of the once-daily Copaxone (20 mg) market. Momenta’s efforts to develop its biosimilars pipeline are also impressive. The company has a partnership with Mylan for six of the latter’s biosimilar. Moreover, we are encouraged by the company’s collaboration with Sandoz. The company also has an exclusive research collaboration and worldwide license agreement with CSL Limited for M230. Momenta’s share price has outperformed the Zacks classified Biomedical and Genetics industry in the last twelve months. However, the discontinuation of patient enrolment in a phase II study on necuparanib on the recommendation of an independent Data Safety Monitoring Board following the unfavorable outcome of a planned interim futility analysis is disappointing." (1/16/2017)

Who owns Momenta Pharmaceuticals stock?

Momenta Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (15.49%), BlackRock, Inc (11.60%), Discovery Capital Management LLC CT (6.48%), Orbimed Advisors LLC (4.28%), Fiera Capital Corp (2.88%) and State Street Corp (2.72%). Company insiders that own Momenta Pharmaceuticals stock include Bruce Leicher, Craig A Wheeler, Elizabeth Stoner, Ganesh Venkataraman Kaundinya, James M Roach, John E Bishop, Michael Franken and Richard P Shea.

Who sold Momenta Pharmaceuticals stock? Who is selling Momenta Pharmaceuticals stock?

Momenta Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Fiera Capital Corp, Dimensional Fund Advisors LP, Oxford Asset Management, Discovery Capital Management LLC CT, Commerzbank Aktiengesellschaft FI, Numeric Investors LLC, Turner Investments LLC and Envestnet Asset Management Inc.. Company insiders that have sold Momenta Pharmaceuticals stock in the last year include Bruce Leicher, Craig A Wheeler, Ganesh Venkataraman Kaundinya, James M Roach, John E Bishop and Richard P Shea.

Who bought Momenta Pharmaceuticals stock? Who is buying Momenta Pharmaceuticals stock?

Momenta Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Opaleye Management Inc., Arrowstreet Capital Limited Partnership, State Street Corp, Renaissance Technologies LLC, Palo Alto Investors LLC, FMR LLC and Guggenheim Capital LLC.

How do I buy Momenta Pharmaceuticals stock?

Shares of Momenta Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Momenta Pharmaceuticals stock cost?

One share of Momenta Pharmaceuticals stock can currently be purchased for approximately $15.10.

Momenta Pharmaceuticals (NASDAQ:MNTA) Chart for Wednesday, February, 22, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Earnings History Chart

Earnings by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Dividend History Chart

Dividend Payments by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Last Updated on 2/22/2017 by MarketBeat.com Staff